Hospital
Deming Hospital Corporation
Deming Hospital Corporation was paid $34.61M by Medicaid between Jan 2018 and Dec 2024, across 240 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoDEMING HOSPITAL CORPORATION
DEMING, NM 88030
DEMING, NM 88030
33aNPI1891075446assigned 08/26/2011
33bProvider typeCritical Access Hospital
28Total paid$34.61M
24GClaims483,086
24DCodes billed240
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New Mexico
Rank by total paid#1 of 6
Median peer was paid$15.48M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71,938 | $4.71M | |
| 2019 | 51,641 | $3.29M | |
| 2020 | 41,344 | $2.76M | |
| 2021 | 61,741 | $4.52M | |
| 2022 | 85,649 | $6.79M | |
| 2023 | 90,467 | $6.36M | |
| 2024incomplete | 80,306 | $6.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 19,652 | 18,025 | $5.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 20,648 | 19,534 | $4.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.2% | 8,415 | 7,685 | $2.84M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 3,361 | 3,186 | $2.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 4,473 | 4,238 | $1.50M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 2,579 | 2,419 | $1.26M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 12,876 | 3,227 | $1.19M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 11,497 | 10,173 | $1.08M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.1% | 7,077 | 6,711 | $1.07M |
| 71045 | Radiologic examination, chest; single view | 2.3% | 10,367 | 9,533 | $806K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 5,787 | 4,792 | $747K |
| 80053 | Comprehensive metabolic panel | 2.1% | 32,399 | 29,074 | $742K |
228 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.0% | 1,790 | $701K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 7,776 | $618K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 1,184 | $567K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 5,191 | $407K |
| G0378 | Hospital observation service, per hour | 1.1% | 895 | $388K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 1,805 | $376K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 8,236 | $366K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 6,159 | $350K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,306 | $330K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,992 | $275K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,298 | $269K |
| 71250 | <1% | 888 | $248K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,871 | $238K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 624 | $233K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,587 | $225K |
| 84484 | <1% | 9,707 | $177K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,238 | $176K |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,520 | $172K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,234 | $172K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,588 | $163K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,336 | $157K |
| 73630 | <1% | 1,625 | $150K | |
| 81001 | <1% | 18,128 | $146K | |
| 80061 | Lipid panel | <1% | 8,052 | $141K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 981 | $139K |
| 85379 | <1% | 2,960 | $135K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,541 | $135K |
| 73610 | <1% | 986 | $129K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,082 | $129K |
| 72100 | <1% | 911 | $125K | |
| 73030 | <1% | 1,068 | $123K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,730 | $109K |
| 84439 | <1% | 4,313 | $106K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,428 | $105K |
| 87040 | <1% | 4,801 | $100K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,010 | $99K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,728 | $93K |
| 83605 | <1% | 3,851 | $89K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,865 | $87K |
| 83880 | <1% | 4,021 | $86K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,426 | $86K |
| 73562 | <1% | 635 | $85K | |
| 83690 | <1% | 7,319 | $79K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,717 | $76K |
| 84703 | <1% | 4,202 | $62K | |
| 76830 | Ultrasound, transvaginal | <1% | 423 | $60K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,064 | $60K |
| 85027 | <1% | 7,632 | $58K | |
| 84702 | <1% | 2,504 | $57K | |
| 73130 | <1% | 554 | $56K | |
| 87081 | <1% | 3,011 | $55K | |
| 83874 | <1% | 1,802 | $53K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,572 | $49K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 463 | $47K |
| 73560 | <1% | 510 | $43K | |
| 73502 | <1% | 506 | $42K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 205 | $39K |
| 76770 | <1% | 241 | $36K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 239 | $36K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 899 | $36K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 819 | $35K |
| 87186 | <1% | 1,881 | $31K | |
| 94761 | <1% | 568 | $30K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,815 | $30K |
| 74018 | <1% | 362 | $28K | |
| 70486 | <1% | 101 | $27K | |
| 73564 | <1% | 172 | $26K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,056 | $26K |
| 86140 | <1% | 2,566 | $26K | |
| 76536 | <1% | 190 | $26K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,621 | $26K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 76 | $26K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 37 | $25K |
| 86900 | <1% | 2,256 | $25K | |
| 86850 | <1% | 2,138 | $25K | |
| 70496 | <1% | 50 | $24K | |
| 73110 | <1% | 253 | $24K | |
| 85007 | <1% | 1,916 | $24K | |
| 85610 | <1% | 3,337 | $24K | |
| 70498 | <1% | 49 | $24K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,057 | $23K |
| 84481 | <1% | 1,651 | $23K | |
| 83735 | <1% | 2,310 | $22K | |
| 82607 | <1% | 1,190 | $19K | |
| 73590 | <1% | 206 | $18K | |
| 97161 | <1% | 423 | $18K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,067 | $18K |
| 82728 | <1% | 1,245 | $18K | |
| 82553 | <1% | 1,075 | $17K | |
| 86803 | <1% | 979 | $17K | |
| 87077 | <1% | 1,996 | $17K | |
| 87340 | <1% | 1,193 | $17K | |
| 86762 | <1% | 804 | $16K | |
| 96376 | <1% | 651 | $16K | |
| 85652 | <1% | 1,998 | $16K | |
| 82962 | <1% | 3,321 | $15K | |
| 84145 | <1% | 627 | $15K | |
| 72131 | <1% | 42 | $14K | |
| 73120 | <1% | 107 | $14K | |
| 82150 | <1% | 1,145 | $14K | |
| 86787 | <1% | 781 | $14K | |
| 86901 | <1% | 2,244 | $14K | |
| 85730 | <1% | 1,407 | $14K | |
| 82043 | <1% | 1,393 | $13K | |
| 87400 | <1% | 704 | $13K | |
| 93971 | <1% | 100 | $13K | |
| 83540 | <1% | 1,431 | $13K | |
| 86592 | <1% | 1,473 | $13K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 294 | $12K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 32 | $12K |
| 77080 | <1% | 111 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,121 | $12K |
| 72040 | <1% | 84 | $12K | |
| 87428 | <1% | 146 | $11K | |
| 73090 | <1% | 126 | $11K | |
| 93017 | <1% | 60 | $11K | |
| 83550 | <1% | 1,056 | $11K | |
| 93970 | <1% | 65 | $11K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,233 | $10K |
| 86703 | <1% | 657 | $10K | |
| 59025 | Fetal non-stress test | <1% | 75 | $9K |
| 85651 | <1% | 837 | $8K | |
| 73080 | <1% | 81 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 189 | $8K |
| 82550 | <1% | 1,574 | $8K | |
| 86780 | <1% | 513 | $8K | |
| 83655 | <1% | 414 | $8K | |
| 96367 | <1% | 213 | $8K | |
| 82746 | <1% | 576 | $8K | |
| 87807 | <1% | 214 | $7K | |
| 72110 | <1% | 61 | $7K | |
| 87650 | <1% | 212 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 162 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,140 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $6K |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 341 | $6K |
| 97035 | <1% | 232 | $5K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 76 | $5K |
| 74021 | <1% | 43 | $5K | |
| 76000 | <1% | 27 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 126 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 126 | $4K |
| 51702 | <1% | 43 | $4K | |
| 84153 | <1% | 276 | $4K | |
| 0002A | <1% | 72 | $3K | |
| 73552 | <1% | 54 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 355 | $3K |
| 73100 | <1% | 28 | $3K | |
| 82570 | <1% | 585 | $3K | |
| 84156 | <1% | 249 | $3K | |
| 84030 | <1% | 336 | $3K | |
| 87070 | <1% | 191 | $3K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 161 | $3K |
| 97010 | <1% | 440 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 118 | $2K |
| 87205 | <1% | 308 | $2K | |
| 97116 | <1% | 74 | $2K | |
| 93925 | <1% | 14 | $2K | |
| 87490 | <1% | 69 | $2K | |
| 80076 | <1% | 157 | $2K | |
| 86038 | <1% | 129 | $2K | |
| 83013 | <1% | 29 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $2K |
| 84403 | <1% | 93 | $2K | |
| 87420 | <1% | 66 | $2K | |
| 87631 | <1% | 12 | $2K | |
| 84100 | <1% | 500 | $2K | |
| 87590 | <1% | 69 | $2K | |
| 96368 | <1% | 184 | $1K | |
| 76010 | <1% | 13 | $1K | |
| 84402 | <1% | 63 | $1K | |
| 97165 | <1% | 25 | $1K | |
| 83001 | <1% | 52 | $1K | |
| 73140 | <1% | 13 | $1K | |
| 82803 | <1% | 37 | $1K | |
| 97162 | <1% | 17 | $961.44 | |
| 73620 | <1% | 16 | $885.50 | |
| 82248 | <1% | 133 | $830.65 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 892 | $827.84 |
| 0001A | <1% | 27 | $783.86 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 50 | $652.18 |
| 82270 | <1% | 116 | $629.52 | |
| 83002 | <1% | 26 | $603.45 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 139 | $589.24 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 595 | $583.25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 232 | $567.32 |
| 94760 | <1% | 35 | $552.16 | |
| 82009 | <1% | 66 | $540.96 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 232 | $531.22 |
| 80074 | <1% | 15 | $531.14 | |
| 85045 | <1% | 115 | $509.81 | |
| 90715 | <1% | 41 | $490.64 | |
| 82140 | <1% | 43 | $490.42 | |
| 82670 | <1% | 12 | $457.20 | |
| 87075 | <1% | 27 | $419.62 | |
| 82247 | <1% | 67 | $369.62 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 159 | $336.38 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 77 | $335.92 |
| 84450 | <1% | 58 | $322.93 | |
| A9270 | Non-covered item or service | <1% | 503 | $308.89 |
| 84550 | <1% | 69 | $264.00 | |
| 82951 | <1% | 12 | $262.37 | |
| 85384 | <1% | 23 | $246.10 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 93 | $229.22 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 604 | $203.41 |
| 82977 | <1% | 28 | $172.74 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 214 | $152.65 |
| 86431 | <1% | 12 | $135.07 | |
| 85018 | <1% | 27 | $130.16 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 40 | $127.46 |
| 87210 | <1% | 13 | $126.67 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 98 | $125.36 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 170 | $95.16 |
| 86593 | <1% | 12 | $87.24 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 87 | $70.54 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 213 | $59.68 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 19 | $49.25 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 33 | $37.50 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $36.35 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 54 | $35.83 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 34 | $23.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 49 | $17.35 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 12 | $14.47 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 109 | $7.49 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OP/AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.